← All trials
NCT07285265
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 27, 2025
- Primary completion
- Nov 6, 2025
- Completion date
- Oct 15, 2026
- First posted
- Dec 16, 2025
- Last posted
- Dec 16, 2025
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Abogen Biosciences Co. Ltd.Lead sponsor
- Abogen Biosciences Co. Ltd.Collaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.